Market openADR
Nanobiotix/$NBTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ticker
$NBTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
108
ISIN
US63009J1079
Website
Nanobiotix Metrics
BasicAdvanced
$184M
-
-$1.61
1.55
-
Price and volume
Market cap
$184M
Beta
1.55
52-week high
$7.51
52-week low
$2.76
Average daily volume
13K
Financial strength
Current ratio
1.043
Quick ratio
0.977
Long term debt to equity
-69.977
Total debt to equity
-77.472
Interest coverage (TTM)
-8.44%
Management effectiveness
Return on assets (TTM)
-52.89%
Return on equity (TTM)
201.73%
Valuation
Price to revenue (TTM)
-22.746
Price to book
-2.5
Price to tangible book (TTM)
-2.5
Price to free cash flow (TTM)
-8.017
Growth
Revenue change (TTM)
-119.86%
Earnings per share change (TTM)
33.47%
3-year revenue growth (CAGR)
39.53%
3-year earnings per share growth (CAGR)
2.08%
What the Analysts think about Nanobiotix
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Nanobiotix Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Nanobiotix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Nanobiotix News
AllArticlesVideos
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewsWire·3 days ago
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
GlobeNewsWire·1 week ago
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $184M as of May 15, 2025.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of May 15, 2025.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.